Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
Future Oncology (London, England)|February 15, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancerMarina C Garassino, Luis Paz-Ares, Rina Hui, et al.Cancer Discovery|August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint BlockadeQu Zhang, Jia Luo, Song Wu, et al.Oncotarget|October 21, 2014
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsGideon M Blumenthal, Joell J Gills, Marc S Ballas, et al.Translational Lung Cancer Research|August 2, 2019
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancerTakefumi Komiya, Regan M Memmott, Gideon M Blumenthal, et al.The Lancet. Oncology|October 12, 2019
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 studyRina Hui, Mustafa Özgüroğlu, Augusto Villegas, et al.The Lancet. Oncology|March 17, 2018
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.Oncotarget|June 2, 2015
Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal boneShigeru Kawabata, M Christine Hollander, Jeeva P Munasinghe, et al.Lung Cancer (Amsterdam, Netherlands)|July 24, 2020
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivoJoell J Gills, Jaclyn Lopiccolo, Junji Tsurutani, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFICJhanelle E Gray, Augusto Villegas, Davey Daniel, et al.Pageof 9